Evaluation of T1 and T2 mapping for non-invasive assessment of HER2 and PD-L1 expression in bladder cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
60 patients with bladder cancer (50 men, 10 women; mean age, 70.
I · Intervention 중재 / 시술
3-T MRI before surgery
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The combined MRI model of T1 and T2 values for PD-L1, achieved AUCs of 0.839 (95% CI: 0.740-0.938). [CONCLUSION] Preliminary evidence suggests that T1 and T2 mapping can yield reproducible quantitative metrics, which may offer a means to non-invasively assess HER2 and PD-L1 expression in bladder cancer.
[OBJECTIVES] The purpose of this study is to investigate the diagnostic performance of T1 and T2 mapping for non-invasive assessment of Human epidermal growth factor receptor 2 (HER2) and programmed d
- 표본수 (n) 29
- p-value P < 0.001
- 95% CI 0.843-0.984
APA
Qin S, Luo H, et al. (2026). Evaluation of T1 and T2 mapping for non-invasive assessment of HER2 and PD-L1 expression in bladder cancer.. Abdominal radiology (New York). https://doi.org/10.1007/s00261-026-05390-8
MLA
Qin S, et al.. "Evaluation of T1 and T2 mapping for non-invasive assessment of HER2 and PD-L1 expression in bladder cancer.." Abdominal radiology (New York), 2026.
PMID
41801382 ↗
Abstract 한글 요약
[OBJECTIVES] The purpose of this study is to investigate the diagnostic performance of T1 and T2 mapping for non-invasive assessment of Human epidermal growth factor receptor 2 (HER2) and programmed death-ligand 1 (PD-L1) expression status in bladder cancer.
[METHODS] In this prospective study, patients with bladder cancer underwent 3-T MRI before surgery. The MRI protocol included T1 mapping and T2 mapping. Both T1 and T2 maps were inline generated after data acquisition. Free-hand 2D regions of interest were drawn around the tumor on the largest tumor section. T1 and T2 values were extracted from ROIs. HER2 and PD-L1 status were determined by immunohistochemistry and FISH or CPS scoring. Univariable and multivariable logistic regression analyses were performed. Model performance was evaluated by ROC analysis, calibration, and decision curve analysis.
[RESULTS] This study included a total of 60 patients with bladder cancer (50 men, 10 women; mean age, 70.60 ± 11.51 years). HER2-high tumors (n = 29) demonstrated significantly lower T1 and T2 values compared with HER2-low tumors (n = 31) (1834.59 ± 345.63 vs. 2401.97 ± 609.48, P < 0.001; 81.85 ± 24.22 vs. 145.01 ± 51.97, P < 0.001). The combined MRI model of T1 and T2 values for HER2, achieved AUCs of 0.923 (95% CI: 0.843-0.984). PD-L1 positive tumors (n = 23) demonstrated significantly lower T1 and T2 values compared with PD-L1 negative tumors (n = 37) (1918.02 ± 347.78 vs. 2258.10 ± 645.74, P < 0.05; 82.72 ± 25.12 vs. 134.23 ± 54.19, P < 0.001). The combined MRI model of T1 and T2 values for PD-L1, achieved AUCs of 0.839 (95% CI: 0.740-0.938).
[CONCLUSION] Preliminary evidence suggests that T1 and T2 mapping can yield reproducible quantitative metrics, which may offer a means to non-invasively assess HER2 and PD-L1 expression in bladder cancer.
[METHODS] In this prospective study, patients with bladder cancer underwent 3-T MRI before surgery. The MRI protocol included T1 mapping and T2 mapping. Both T1 and T2 maps were inline generated after data acquisition. Free-hand 2D regions of interest were drawn around the tumor on the largest tumor section. T1 and T2 values were extracted from ROIs. HER2 and PD-L1 status were determined by immunohistochemistry and FISH or CPS scoring. Univariable and multivariable logistic regression analyses were performed. Model performance was evaluated by ROC analysis, calibration, and decision curve analysis.
[RESULTS] This study included a total of 60 patients with bladder cancer (50 men, 10 women; mean age, 70.60 ± 11.51 years). HER2-high tumors (n = 29) demonstrated significantly lower T1 and T2 values compared with HER2-low tumors (n = 31) (1834.59 ± 345.63 vs. 2401.97 ± 609.48, P < 0.001; 81.85 ± 24.22 vs. 145.01 ± 51.97, P < 0.001). The combined MRI model of T1 and T2 values for HER2, achieved AUCs of 0.923 (95% CI: 0.843-0.984). PD-L1 positive tumors (n = 23) demonstrated significantly lower T1 and T2 values compared with PD-L1 negative tumors (n = 37) (1918.02 ± 347.78 vs. 2258.10 ± 645.74, P < 0.05; 82.72 ± 25.12 vs. 134.23 ± 54.19, P < 0.001). The combined MRI model of T1 and T2 values for PD-L1, achieved AUCs of 0.839 (95% CI: 0.740-0.938).
[CONCLUSION] Preliminary evidence suggests that T1 and T2 mapping can yield reproducible quantitative metrics, which may offer a means to non-invasively assess HER2 and PD-L1 expression in bladder cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Intratumoral spatial heterogeneity at non-contrast CT predicts histological grading of invasive pulmonary adenocarcinoma: a multicenter retrospective study.
- Heavy metal exposure and cancer risk: Findings from a Mendelian randomization study.
- First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study.
- A Case Report of Primary Pulmonary Lymphoepithelioma-Like Carcinoma with "Harmful" Pseudoprogression and a Pathological Complete Response (pCR) after Immunotherapy Plus Radiotherapy.
- Research progress of gut microbiota and its metabolites in polycystic ovary syndrome.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Whole-body MRI for staging and follow-up of primary musculoskeletal tumours: a systematic review.
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Revisiting the OGIPRO Trial: Dynamic Electronic Patient-Reported Outcomes Compared with EQ-5D-5L in HER2-Positive Breast Cancer.
- Multifocal anaplastic astrocytoma mimicking primary central nervous system lymphoma: A case report.
- Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection.